Skip to main content
SDGR logo

SDGR · Schrodinger, Inc. · Documents

Track SDGR — free
Market Cap
$2.04B
Shares
75.08M
Volume · Nov 19 97.88K Avg daily vol (3M) 2.06M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $255.87M up 23.3% 10-K filed Feb 25, 2026 Quarterly report FY2026 Q3 Revenue $64.49M up 18.7% 10-Q filed Nov 4, 2026 Latest results Raises 2026 outlook and clarifies SGR-1505 study status 8-K filed Nov 4, 2026 Earnings call Q3 2026 earnings call Held Nov 4, 2026
2026
Nov 10
Investor event
ACV Growth Guided at 12 to 17%

Schrodinger expects ACV to increase 12 to 17% this year off of 198; Bunsen remains in beta and the company is seeing license growth. The hosted transition targets 75% hosted by 2028.

4 source passages
every part of that involves a chemical discovered by Schrodinger's platform, or I shouldn't say necessarily discovered, but influenced by Schrodinger's platform. So our ACV is expected to increase 12 to 17% this year off of 198. Again, Bunsen is still in beta. So we've announced our transaction with Bristol Myers, but it's still in beta. I think we're pleased with what it's done on license growth, but some of that growth is still to come. But as we get through this transition and the hosted percentage increases to a place We've targeted 75% by 2028. Open the document at this passage
Nov 4
Earnings call
Raises ACV and drug discovery guidance after 17% ACV growth

Schrodinger raised full-year 2026 ACV guidance to $222 to $232 million and drug discovery revenue guidance to $75 to $85 million after 17% third-quarter ACV growth.

4 source passages
Welcome to Schrodinger's conference call to review third quarter 2026 financial results. Third quarter ACV was $44.7 million, which represents 17% growth year-over-year We now expect full-year 2026 ACV to be in the range of $222 to $232 million We now expect drug discovery revenue to be in the range of $75 to $85 million Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 19%, but quarterly net loss widens

Schrodinger generated revenue of $64.5 million for the three months ended September 30, 2026, up 19% from $54.3 million, while net loss widened to $37.7 million from $32.8 million.

Revenue $64.49M ▲ 18.7% Net loss $37.71M Diluted EPS -$0.50
Read from the MD&A section
Source passage
We generated revenue of $64.5 million and $54.3 million during the three months ended September 30, 2026 and 2025, respectively, representing a year-over-year increase of 19%. Our net loss for the three months ended September 30, 2026 was $37.7 million and our net loss for the three months ended September 30, 2025 was $32.8 million. Open the document at this passage
Nov 4
Current report 8-K
Raises 2026 outlook and clarifies SGR-1505 study status

Schrödinger reported third-quarter ACV of $44.7 million, up 17%, and raised 2026 ACV guidance to $222 million to $232 million and drug discovery revenue guidance to $75 million to $85 million. It clarified that no SGR-1505 combination study had been initiated under its FDA-cleared protocol.

Financial results, Regulation FD disclosure
5 source passages
New York, November 4, 2026 – Schrödinger, Inc. (Nasdaq: SDGR) today announced financial results for the quarter ended September 30, 2026. ACV was $44.7 million, a 17% increase, and $214 million on a trailing four-quarter basis. ACV is expected to range from $222 million to $232 million, representing 12-17% growth over 2025, compared to the prior expectation of $218 million to $228 million or 10-15% growth over 2025. Drug discovery revenue is expected to range from $75 million to $85 million, compared to the prior expectation of $65 million to $75 million. The Company has in fact not initiated a combination study of SGR-1505 under its FDA-cleared protocol Open the document at this passage
Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $58.89M ▲ 7.5% Net income $5.98M Diluted EPS $0.08
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $58.59M ▼ 1.6% Net loss $60.03M Diluted EPS -$0.81
Feb 25
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $255.87M ▲ 23.3% Net loss $103.27M Diluted EPS -$1.41
2025
Feb 26
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $207.54M ▼ 4.2% Net loss $187.12M Diluted EPS -$2.57
2024
Showing 1–50 of 143 documents
Key facts CIK 1490978 CUSIP 80810D103 13F (30d) 285 filings 257 filers Visit website Investor relations